Generate topline data from the Phase 3 HERO trial
The company cancelled or abandoned the commitment
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 31 Mar 2025
- Due
- 31 Mar 2026
- Withdrawn
- 1 Jun 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Ongoing ARD-101 Phase 3 HERO trial to treat hyperphagia associated with PWS is expected to generate topline data in early 2026.”
What we found
Evidence strength A What the grades mean
The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Mar 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +183 days
- 3 versions
-
Version 1 · original · stated 31 Mar 2025
Deadline 31 Mar 2026 (“early 2026”) · wording expected
-
Version 2 · stated 13 Aug 2025
Deadline 30 Sep 2026 (“in the third quarter of 2026”) · wording expected
“Topline data from the Phase 3 HERO trial evaluating ARD-101 for the treatment of hyperphagia associated with PWS is expected in the third quarter of 2026.”
-
Version 3 · stated 10 Feb 2026
Deadline 30 Sep 2026 (“in the third quarter of 2026”) · wording firm
“Enrollment in HERO is progressing steadily and remains on track to report topline data in the third quarter of 2026.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Generate
- Deliverable
- Phase 3 HERO trial topline data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Aardvark Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-AARD-002608 · Corrections policy